Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 185 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Epilepsy Clear all
Active, not recruiting Not applicable Interventional

Goals for Epilepsy Clinic Visits Trial

NCT05928598
View directory record Official record
Conditions
Drug Resistant Epilepsy
Interventions
Survey questionnaires, Epilepsy Visit Planner, Questionnaires for Providers
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)

NCT02383407
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
Medtronic Deep Brain Stimulation
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 22, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional Results available

Acute Recording of Stereotyped High-Frequency Oscillations

NCT05439655
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Not applicable Interventional

Long-term Cardiac Monitoring in Epilepsy

NCT03955432
View directory record Official record
Conditions
Focal Epilepsy, Intractable Epilepsy, Epileptic Encephalopathy, Lennox Gastaut Syndrome, Symptomatic Epilepsy, Generalized Epilepsy
Interventions
Reveal LINQ ICM System
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 1:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125
View directory record Official record
Conditions
Dravet Syndrome
Interventions
zorevunersen, Sham Comparator
Drug · Other
Lead sponsor
Stoke Therapeutics, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 2 Interventional

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

NCT00141414
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2007 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Phase 2 Interventional Results available

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03370120
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Chandler, Arizona • La Jolla, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740
View directory record Official record
Conditions
Epilepsy
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Optimal Stimulation Parameters to Disrupt Epileptiform Activity

NCT06141668
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
Neurostimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
No Longer Available No phase listed Expanded access

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

NCT04457687
View directory record Official record
Conditions
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Recruiting No phase listed Observational

Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

NCT07110454
View directory record Official record
Conditions
Epilepsy, Epilepsy (Treatment Refractory)
Interventions
Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
Device
Lead sponsor
Epiminder America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional

RNS System NAUTILUS Study

NCT05147571
View directory record Official record
Conditions
Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
Interventions
Responsive stimulation, Sham stimulation
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional

Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs

NCT06545643
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Dreem headband
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder

NCT03572933
View directory record Official record
Conditions
CDKL5 Deficiency Disorder
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
2 Years to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 22, 2026, 1:09 AM EDT
Completed No phase listed Observational

Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death

NCT00203333
View directory record Official record
Conditions
Refractory Epilepsy, Arrhythmia, Sudden Death
Interventions
Medtronic REVEAL
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
16 Years to 49 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Modulation of Emotion Perception in Humans Via Amygdala Stimulation

NCT05292183
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
Electrical Stimulation
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 22, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional

Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

NCT06425029
View directory record Official record
Conditions
Epilepsy, Refractory Epilepsy, Music
Interventions
Experimental Intervention (Music A), Active Comparator Intervention (Music B), Active Comparator Intervention (Music C)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Worcester, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 22, 2026, 1:09 AM EDT
Enrolling by invitation Not applicable Interventional

Neural Mechanisms of Social Attribution From Faces

NCT07822178
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Phase 1 Interventional

Brain Infusion of Muscimol to Treat Epilepsy

NCT00005925
View directory record Official record
Conditions
Epilepsy
Interventions
Muscimol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 1:09 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Localizing Epileptic Networks Using MRI and iEEG

NCT04649008
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
Interventions
3T Magnetic Resonance Imaging, Intracranial electroencephalography recordings, 7T Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 1:09 AM EDT
Not listed Not applicable Interventional

Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy

NCT03857074
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable
Interventions
Green Light Exposure
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 22, 2026, 1:09 AM EDT
Enrolling by invitation Not applicable Interventional

Neuronal Mechanisms of Learning and Utilizing Abstract Representations

NCT07454785
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 1:09 AM EDT